

STUDY PROTOCOL

Open Access



The TRIPLEX study: use of patient-derived tumor organoids as an innovative tool for precision medicine in triple-negative breast cancer

Jordane Divoux^{1,2,3}, Romane Florent^{1,2,3}, Margaux Jacobs⁴, Justine Lequesne⁵, Jean-Michel Grellard⁵, Chankannira San⁵, Sara Grossi⁵, Katia Kerdja⁵, Bénédicte Clarisse⁵, Gwenaëlle Boudier⁵, François Cherifi⁴, Mélanie Briand^{1,6}, Enora Dolivet^{1,7}, Alisson Johnson^{4,5}, Brice Dubois⁸, Valentin Harter⁸, Joëlle Lacroix⁹, Charlotte Raboutet⁹, Brigitte Marie⁹, Nathalie Rousseau^{2,10}, Cécile Blanc-Fournier^{1,6,10,11}, Dominique Vaur¹², Martin Figeac¹³, Laurent Poulain^{1,3,6}, Louis-Bastien Weiswald^{1,2,3,14*†} and George Emile^{4,5,15*†}

Abstract

Background Triple negative breast cancers (TNBC) account for approximately 15% of all breast cancers and are associated with a shorter median survival mainly due to locally advanced tumor and high risk of metastasis. The current neoadjuvant treatment for TNBC consists of a regimen of immune checkpoint blocker and chemotherapy (chemo-ICB). Despite the frequent use of this combination for TNBC treatment, moderate results are observed and its clinical benefit in TNBC remains difficult to predict. Patient-derived tumor organoids (PDTO) are 3D in vitro cellular structures obtained from patient's tumor samples. More and more evidence suggest that these models could predict the response of the tumor from which they are derived. PDTO may thus be used as a tool to predict chemo-ICB efficacy in TNBC patients.

Method The TRIPLEX study is a single-center observational study conducted to investigate the feasibility of generating PDTO from TNBC and to evaluate their ability to predict clinical response. PDTO will be obtained after the dissociation of biopsies and embedding into extra cellular matrix. PDTO will be cultured in a medium supplemented with growth factors and signal pathway inhibitors. Molecular and histological analyses will be performed on established PDTO lines to validate their phenotypic proximity with the original tumor. Response of PDTO to chemo-ICB will be assessed using co-cultures with autologous immune cells collected from patient blood samples. PDTO response will finally be compared with the response of the patient to evaluate the predictive potential of the model.

Discussion This study will allow to assess the feasibility of using PDTO as predictive tools for the evaluation of the response of TNBC patients to treatments. In the event that PDTO could faithfully predict patient response in clinically relevant time frames, a prospective clinical trial could be designed to use PDTO to guide clinical decision. This study will also permit the establishment of a living biobank of TNBC PDTO usable for future innovative strategies evaluation.

[†]Louis-Bastien Weiswald and George Emile contributed equally to this work.

*Correspondence:

Louis-Bastien Weiswald
lb.weiswald@baclesse.unicancer.fr
George Emile
g.emile@baclesse.unicancer.fr

Full list of author information is available at the end of the article



Trial registration The clinical trial (version 1.2) has been validated by local research ethic committee on December 30th 2021 and registered at ClinicalTrials.gov with the identifier NCT05404321 on June 3rd 2022, version 1.2.

Keywords Triple negative breast cancer, Patient-derived tumor organoids, Predictive functional assays, Chemo-immunotherapy

Background

Breast cancer: epidemiology and therapeutic management

Breast cancer is the most common cancer worldwide and accounts for 1 in 8 cancer diagnoses with a total of 2.3 million new cases in both sexes combined [1]. It represents about a quarter of all cancer cases in females and was by far the most commonly diagnosed cancer in women in 2020 [2]. An estimated 685,000 women died worldwide from breast cancer in 2020, corresponding to 16% of cancer deaths in women [3]. Classification of breast cancer is done through the analysis of the expression of hormone receptors (estrogen/progesterone) and human epidermal growth factor receptor 2 (HER2). They are regrouped as hormone receptors-positive, HER2 positive or triple negative. Triple negative breast cancer (TNBC) represents about 15% of all breast cancers, it occurs generally in younger patients and is associated with a higher risk of metastasis and worse survival [4]. These tumors are more likely to be locally advanced and require neoadjuvant treatment [5]. The current neoadjuvant regimen for TNBC is based on the KEYNOTE-522 trial and consists of four cycles of an immune checkpoint blocker (ICB), pembrolizumab every 3 weeks plus paclitaxel and carboplatin, followed by 4 cycles of pembrolizumab plus doxorubicin–cyclophosphamide or epirubicin–cyclophosphamide [6], two regimens summarized as chemo-ICB in the following text. Based on the same study, the post neoadjuvant treatment for TNBC consists of the continuation of pembrolizumab for 9 additional cycles. ICB is thus nowadays a major therapeutic option for TNBC care although other adjuvant treatments can be used such as capecitabine for 6 to 8 cycles [7] or olaparib for patients with a BRCA 1 or 2 mutation [8].

Despite the frequent use of chemo-ICB for TNBC treatment, moderate results continue to be observed for this regimen and the clinical benefit of ICB in TNBC remains hard to predict. This is explained by the fact that patients show highly variable response with a minority of good responders currently not clearly identified. To date, only one biomarker is clinically validated to predict ICB efficacy in TNBC and consists in the evaluation of PD-L1 expression (FDA 2020). However, despite its predictive value in advanced TNBC, PD-L1 expression failed to discriminate responding and non-responding patients in early TNBC, in which ICB efficacy seems to

be higher [9]. Other biomarkers are currently considered such as tumor mutational burden (TMB), tumor infiltrating leucocytes (TILs) or immune genes signatures but their predictive value is still controversial and their use is for now restricted to general prognosis [9]. The development of an efficient test to predict chemo-ICB efficacy in early TNBC is thus a prerequisite to make the best use of it and drive TNBC patients care toward precision medicine.

Patient derived tumor organoid (PDTO): an innovative tool for precision medicine

The essence of precision medicine in oncology is to give the right treatment to the right patient, i.e. to the patient which will have the best chance to benefit from a given treatment. So far, the predominant method to reach this goal was to select the treatment based on biomarkers able to discriminate responder from non-responder patient but today there are growing strategies focusing on functional assays [10]. These assays are based on direct exposure of cancer tissues derived from patients to drugs to evaluate the response to treatments. They thus assume the tumor on its all and consider all its features (histological and molecular) without any need of prior characterization. Different models can be used to run functional assays [11], such as Patient-Derived Tumor Organoids (PDTO) which are now considered as a relevant model to bridge the gap between cell lines and patient-derived xenograft mouse models. PDTO are three-dimensional in vitro cellular structures obtained after dissociation of tumor samples and embedding of tumor cells in extracellular matrix within medium containing a cocktail of growth factors and signaling pathway inhibitors. Long-term PDTO lines displaying similar morphologic and genetic features with their original tumor have been successfully established from a range of malignancies [12], including breast cancer [13]. Increasing evidence indicate that the ex vivo response of PDTO may correlate with the response of the original tumor. PDTO have thus been shown to be able to predict the response to chemotherapy of gastrointestinal [14] and pancreatic tumors [15] as well as the sensitivity of colorectal cancers to radiotherapy [16]. Furthermore, two independent studies showed that PDTO established from different types of breast cancers, including TNBC, displayed histological and genomic concordance with parental tumors as well

as sensitivities to standard of care corresponding to their tumor type (chemotherapy, hormonotherapy and HER2 antibodies) [17, 18]. Given the predictive value of PDTO, their use to predict chemo-ICB efficacy against TNBC may have promising potential for the future. Nevertheless, as immunotherapy efficacy requires the presence of a functional immune system, enhancement of PDTO with autologous immune cells (iPDTO) is critical and elicits a significant interest from the scientific community. Several attempts have been described to generate iPDTO either by using immune cells infiltrating the tumor of origin [19–26] or from peripheral blood mononuclear cells (PBMC) [27–29]. Still, coculture of PDTO and immune cells is facing a number of challenges which will need to be addressed before the availability an off-the-shelf predictive tool.

Method/design

The TRIPLEX study is a single-center observational study conducted at Comprehensive Cancer Centre François Baclesse to investigate the feasibility of generating and testing PDTO from TNBC for evaluation of

response to treatments (Fig. 1). The TRIPLEX study and this manuscript have been written in accordance with standard protocol items, namely recommendations for interventional trials (SPIRIT). The method and design of this study is based on the ORGAVADS study described by Perréard et al. [30].

Study objectives and endpoints

The main objective of the study is to assess the feasibility of using PDTO from TNBC as a tool for predicting response to treatments.

The secondary objectives are: i) to assess the feasibility of in vitro functional assays for evaluation of sensitivity to treatments; ii) to identify biomarkers for predicting response to treatments in tumor and blood samples; iii) to evaluate the concordance between the response of PDTO to treatments (chemotherapy, targeted therapies and immunotherapy) and the clinical response.

Study population

Eligibility criteria are described in Table 1. The TRIPLEX study focuses on patients with early stage (I-III) TNBC who




Fig. 1 TRIPLEX study design (created with Biorender.com)

Table 1 TRIPLEX study inclusion and exclusion criteria

Inclusion criteria	Exclusion criteria
Patient over 18 years of age	Pregnant women
Patient with early stage (I-III) TNBC who needs to have clips placed before neoadjuvant chemotherapy	Persons deprived of liberty or under guardianship (including curatorship)
Patient affiliated to a social security system	History of any other clinically active malignancy in the last 5 years prior to inclusion
Proficiency in French language	
Patient having signed the consent to participate in the study	

undergo clip placement before neoadjuvant chemotherapy at Comprehensive Cancer Centre François Baclesse.

Study assessment

The study was approved by the “North-West I” ethical committee (IDRCB: 2021-A02676-35). After the screening of patients according to criteria, a proposal for enrollment will be given by the clinician which will inform all patients enrolled in the study that their biological samples could be used for research purposes. An identification number will be assigned to each patient to be used throughout the study. All patients participating may object at any time, leading to the prompt disposal of their tissue and any derived material, as well as the cessation of data collection. The enrollment period of the study will be four years.

Medical data collection

In order to correlate the biological data obtained on the initial tumor with the response to *ex vivo* treatments and the response observed in the clinic, the patients’ clinical data will be collected in the study from medical records. The collected data are summarized in Table 2.

Biological collection

Tumor

During the patient’s care, a breast clip is placed under local anesthesia at the site of the tumor in order to locate it for its excision after the neoadjuvant treatment. During this

medical act, three tumor samples will be collected through a core biopsy. Tumor samples will be then sent directly in sterile vials filled with cold culture medium supplemented with a Rho-kinase inhibitor (Y-27632) to the laboratory.

Blood

Blood samples are collected before the clip placement as part of regular medical care. No blood draw will be done specifically for this study. An additional volume of blood will be collected in seven 5 ml EDTA tubes and transported to the laboratories to be processed.

Biological sample processing

Tumor sample processing

Different procedures will be carried out on the three tumor samples: 1) one sample will be processed for the isolation of viable cells and PDO establishment; 2) one sample will be snap frozen and stored at -80 °C for molecular analyses; 3) one sample will be fixed in paraformaldehyde for paraffin embedding and subsequent histopathological analysis and immunohistochemistry. All tumor samples will be stored in the Biological Resource Center (BRC) ‘Tumorotheque de Caen Basse-Normandie’ (TCBN).

Isolation of PBMC

PBMC will be isolated from blood by density gradient centrifugation using Ficoll-Paque in Leucosep tubes. Cells will be resuspended in cold culture media, and counted. PBMC will be then resuspended in freezing solution (10% DMSO, 90% FBS), aliquoted (about 5 cryovials, 4.10^6 cells/cryovial), and frozen with gradually decreasing temperatures (1°C/min) to -80°C before long-term storage at liquid nitrogen temperatures and stored in the BRC TCBN.

Establishment of panel of PDO

Tumor samples will be enzymatically and mechanically dissociated to obtain isolated cells or small cell clusters. Cells will be embedded in an extracellular matrix and

Table 2 Medical data collected in the TRIPLEX study

Clinical parameters
Age
History of the disease (diagnosis, mutations status, management)
History of other cancers or not
Surgical procedure
Response to treatment
Recurrence (type, date, location)
Date of death

cultured in a medium supplemented with growth factors and signal pathway inhibitors [Advanced DMEM (Gibco) supplemented with 100 UI/mL of penicillin and streptomycin (Gibco), 1% GlutaMAX (Gibco), 1X B27 (Gibco), 5 mM Nicotinamide (Sigma-Aldrich), 1.25 mM N-Acetyl-L-Cysteine (Sigma-Aldrich), 50 µg/mL Primocin (InvivoGen), 100 ng/mL Noggin (PeproTech), 5 nM Neuregulin 1 (PeproTech), 5 µM Y27632 (Interchim), 20 ng/mL FGF-10 (PeproTech), 500 nM A-83-01 (PeproTech), 50 ng/mL EGF (PeproTech), 5 ng/ml FGF-7 (PeproTech), 1 µM SB202190 (PeproTech) and 10% RSP01- conditioned media (Cultrex HA-R-Spondin-1-Fc 293 T, Amsbio)]. Culture medium will be changed twice a week. Once formed, PDTO will be dissociated and reseeded to amplify them for experimental purposes. Cryovials will be prepared at regular intervals by dissociating and resuspending PDTO in Recovery Cell Culture Freezing Medium (Gibco) prior to be biobanked in liquid nitrogen. PDTO lines will be considered as established when it will be maintained for more than 3 passages. For each established PDTO line, samples will be kept frozen for DNA/RNA/protein analysis and others will be embedded in paraffin for histopathological analysis.

Coculture of PDTO with immune cells

PDTO specific autologous T cells will be induced according to modified version of the protocol described in Dijkstra et al. [29]. Briefly, PBMC will be activated with the corresponding PDTO lysate and specific T cells clones will be isolated based on their expression of CD154 and CD137 markers using flow cytometry sorting. Once isolated and their purity controlled, specific T cells will be amplified by the use of a stimulation matrix and then cryopreserved. A quality control will be performed before cryopreservation by flow cytometry to check for reactivity against PDTO using CD107a expression and cytokines production after antigen re-stimulation. Once produced and checked for antigen specificity, PDTO-specific T cells will be cocultured with PDTO to produce iPDTO for the evaluation of response to immunotherapy.

Evaluation of the response to treatment and correlation with clinical data

iPDTO will be done at several effector:target ratios to determine the sensitivity of PDTO to T cells killing. Viability of PDTO will be evaluated all along the assay thanks to the use of Caspase 3 fluorescent probes imaged by IncuCyte (Sartorius). The phenotype of T cells (CD107a expression and cytokines production) will be evaluated at the end of the coculture by flow cytometry. The process will be repeated in the presence of a combination of chemotherapy and ICB to evaluate the impact of the treatment (Fig. 2). This information

will be re summarized in the “immune sensitivity” and the “chemo-ICB sensitivity” scores that will be compared with the patient’s clinical response to assess the predictive capacity of the model. The clinical response of the patient will be evaluated through a Residual Cancer Burden (RCB) score established by immunochemistry. Clinical responses will be classified as RCB-0 or pCR (Pathological Complete Response), RCB-I (minimal residual disease), RCB-II (moderate residual disease) and RCB-III (extensive residual disease).

Evaluation of PDTO model relevance and identification of potential predictive biomarkers

Transcriptomic analysis

RNA analysis will be performed according to the protocol described in Perréard et al. [30]. Briefly, total RNA will be extracted using the Nucleospin RNA kit (Macherey Nagel, Hoerd) and libraries will be made with the QuantSeq 3’RNA Library Kit. Once produced, the final library will be purified and deposited on High sensitivity DNA chip to be controlled on Agilent bioanalyzer 2100 and sequenced on NovaSeq 6000 (Illumina). Elimination of poor-quality regions and poly(A) of reads will be done through the use of the fastp program. Read alignments will be performed using the program STAR with the genome reference human (GRCh38) and the reference gene annotations (Ensembl). Reads counts will be done using FeatureCount and statistical analysis will be realized with the R/bioconductor package DESeq2.

Copy number variations analysis by low-pass whole genome sequencing (WGS)

WGS will be performed using Illumina DNA PCR Free prep kit, starting with 500ng of DNA. Library will be prepared with HMMcopy and ichorCNA.

Transcriptome and CNV analysis

Analysis of intra reproducibility and differences between original tumors and PDTO will be assessed by PCA and unsupervised hierarchical clustering as described in Perréard et al. [30].

Statistical consideration

Sample size determination

To estimate the PDTO establishment rate, assumed around 30%, with a 95% confidence interval of 10% width, 141 tumor samples will be required. Anticipating 15% of non-assessable samples, it is planned to include 163 patients. We expect to be able to correlate the clinical response with the response to the treatments obtained ex vivo on about 30% of included patients, namely 49 PDTO. With such a sample, the disagreement rate




Fig. 2 PDTO generation and treatment (created with Biorender.com)

between clinical response and ex vivo response will be estimated with a 95% confidence interval of 20% width (estimating this disagreement rate around 15%).

Statistical analyses

Qualitative variables will be described using the sample numbers and percentages. Quantitative variables will be described using the mean (\pm standard deviation) or the median and the range if normality hypothesis is not verified.

To address the primary objective, the rate of successful PDTO establishment, i.e., the rate of tumor samples usable for predictive functional assays based on PDTO, will be estimated with its 95% confidence interval. Then, PDTO response to treatment will be correlated with the clinical response by computing the Cohen’s kappa coefficient. Associations between biological parameters and clinical response will be assessed by one-way analysis of variance (or the non-parametric Kruskal–Wallis test, if necessary). Receiver Operating Characteristic (ROC) curves and a logistic regression model will also be used to identify predictive factors of clinical response. An alpha level of 5% will be considered to indicate statistical significance for each statistical analysis and confidence interval.

Data management

The tumor collections of the BRC TCBN are associated to database, where information about the patient, the histology and pathology of the tumor and the treatment are stored. In the frame of this present application, follow-up

data of the patients included in the study (occurrence of local or locoregional relapse, distant metastasis, second primary cancer, death after ICB treatment) will be retrieved from medical charts by a Clinical Research Associate. Physicians will regularly confirm relapse and/or distant metastasis by reviewing radiological examination reports.

Discussion

PDTO are preclinical models that recapitulate closely the original tumors in terms of morphological and molecular characteristics [31]. Recent studies have demonstrated that PDTO could potentially mirror the clinical responses of patients to treatments but the sample size of most studies is too small or too heterogenous to clearly conclude about its predictive value in clinical practice [12]. In particular, the concordance between response of PDTO and response of breast cancer patient to tamoxifen was studied in only 2 patients [13]. It is therefore crucial to demonstrate the predictive value of PDTO based on large and homogenous patient cohort.

In this clinical study, we propose to establish PDTO from biopsies of TNBC patients who will undergo neoadjuvant therapy. These biopsies will be collected at the tissue marker clip placement. This allows the direct comparison between the response of the patient after neoadjuvant treatment (assessed by Residual Cancer Burden (RCB)) and the response of PDTO after exposure to the same treatment. Our goal is to show that PDTO from TNBC patients could serve as a powerful tool for predicting patient response to treatments and to identify

predictive molecular signature in PDTO, tumor and blood samples. An additional aim is to use the PDTO generated during this study to assess new therapeutic compounds and strategies. In the event that PDTO could faithfully predict patient response in clinically relevant time frames, a prospective clinical trial could be designed to use PDTO for guiding neoadjuvant therapy clinical decision making.

Another perspective will be to generate PDTO from biopsies of recurrent breast cancers to help clinicians determine the most optimal therapy. In this manner, it is crucial to collect biopsies at the right time to take into consideration the genetic and epigenetic changes associated with the first line of treatment. Furthermore, a comparison of the response of the PDTO obtained at two different times (early and recurrent) may also inform on the predictive potential of PDTO derived from early biopsies to predict the response to following lines of treatments.

Abbreviations

BRC	Biological Resource Center
BRCA	BRest CAncer
CD	Cluster Differentiation
CNV	Copy Number Variation
DMEM	Dulbecco's Modified Eagle Medium
DMSO	DiMethyl SulFOxide
DNA	DeoxyriboNucleic Acid
EDTA	EthyleneDiamineTetraacetic Acid
EGF	Epidermal Growth Factor
ER	Estrogen Receptor
FBS	Fetal Bovine Serum
FGF	Fibroblast Growth Factor
HER2	Human Epidermal Growth Factor Receptor-2
ICB	Immune Checkpoint Blockade
iPDTO	Immune enhanced PDTO
PBMC	Peripheral Blood Mononuclear Cells
PCA	Principal Component Analysis
PD-L1	Programmed Death-Ligand 1
PDTO	Patient-Derived Tumor Organoid
PR	Progesterone Receptor
RCB	Residual Cancer Burden
RNA	RiboNucleic Acid
ROC	Receiver Operating Characteristic
RSPO1	R-SPONdin-1
SPIRIT	Standard Protocol Items: Recommendations for Interventional Trials
TCBN	"Tumorothèque de Caen Basse Normandie"
TILs	Tumor Infiltrating Leucocytes
TMB	Tumor Mutational Burden
TNBC	Triple Negative Breast Cancer
TRIPLEX	TRIPLE-negative cancer breast EXvivo
WGS	Whole Genome Sequencing

Acknowledgements

The ORGAPRED core facility 'Tumor organoids for research and predicting response to treatment' is supported by the Normandy County Council, the European Union within the framework of the Operational Programme ERDF/ESF 2014-2020 and the French state which was conducted as part of the planning contract 2015-2020 between the State and the Lower Normandie Region (ORGAPRED, POLARIS and EquipInnovCaen2022-PLATONUS ONE projects). We thank the donors, the Lions clubs of Normandy, Vaincrabe and the other foundations for their support of the projects carried out by our teams on PDTO. We

are grateful to Inserm, University of Caen Normandy and the Comprehensive Cancer Center François Baclesse for their support in the implementation of these activities.

Authors' contributions

JD, RF, LBW and GE wrote the manuscript. JD, RF, LP, LBW, GE, MB, JL and JMG devised the study concept and design. JL was responsible for overseeing the statistical section. All authors contributed to the study protocol, read and approved the final manuscript. Each author has been sufficiently involved in the work to take public responsibility for appropriate portions of the content. Figures and illustrations were designed and created by JD, LBW, and RF. Funding was obtained by LBW, LP and GE.

Funding

This work is supported by "La Rochambelle", the "Cancéropôle Nord Ouest" under the structuring project "OrgaNO" and is part of the "ORGATHEREX" European project, co-funded by the Normandy County Council, the European Union within the framework of the Operational Program ERDF/ESF 2014-2020. The funders had no participation in study design, data management, or publication management.

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

This study and all its methods will be carried out in accordance with relevant guidelines and have received ethical approval from the Comité de Protection des Personnes Nord-Ouest I (N°EudraCT: 2021-A02676-35) in June 2022. This committee is independent and not related with any affiliation of the authors. Any subsequent will of modification of the protocol would be submitted to agreement of the committee. The clinical trial has been registered at Clinical-Trials.gov with the identifier NCT05404321 on June 3rd 2022. The study will be explained to the patients by the oncologists and an informed consent form will be obtained from all participants.

Consent to publication

Not applicable.

Competing interests

The authors declare no competing interests.

Author details

¹INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers), Université de Caen Normandie, Caen, France. ²Comprehensive Cancer Center François Baclesse, UNICANCER, Caen, France. ³US PLATON, ORGAPRED Core Facility, Université de Caen Normandie, Caen, France. ⁴Comprehensive Cancer Center François Baclesse, Breast Cancer Unit, UNICANCER, Institut Normand du Sein, Caen, France. ⁵Comprehensive Cancer Center François Baclesse, Clinical Research Department, UNICANCER, Caen, France. ⁶US PLATON, Biological Resource Center 'OvaRessources', Université de Caen Normandie, Caen, France. ⁷Comprehensive Cancer Center François Baclesse, Department of Surgery, UNICANCER, Caen, France. ⁸Comprehensive Cancer Center François Baclesse, North-West Canceropole Data Center, UNICANCER, Caen, France. ⁹Comprehensive Cancer Center François Baclesse, Department of Radiology, UNICANCER, Caen, France. ¹⁰Biological Resource Center 'Tumorothèque de Caen Basse-Normandie', IRCBN Institut Régional du Cancer Basse Normandie, Caen, France. ¹¹Comprehensive Cancer Center François Baclesse, Department of Biopathology, UNICANCER, Caen, France. ¹²Comprehensive Cancer Center François Baclesse, Department of Cancer Biology and Genetics, UNICANCER, Caen, France. ¹³CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UAR 2014 - PLBS, University of Lille, Lille, France. ¹⁴INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), Comprehensive Cancer Center François Baclesse, 3 Avenue du Général Harris, BP 45026, Caen Cedex 05 14 076, France. ¹⁵Breast Cancer Unit, Comprehensive Cancer Center François Baclesse, 3 Avenue du Général Harris, BP 45026, Caen Cedex 05 14 076, France.

Received: 17 July 2023 Accepted: 1 September 2023
Published online: 19 September 2023

References

- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2021;71(3):209–49.
- Heer E, Harper A, Escandor N, Sung H, McCormack V, Fidler-Benaoudia MM. Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study. *Lancet Glob Health*. 2020;8(8):e1027–37.
- Anderson BO, Ilbawi AM, Fidarova E, Weiderpass E, Stevens L, Abdel-Wahab M, et al. The global breast cancer initiative: a strategic collaboration to strengthen health care for non-communicable diseases. *Lancet Oncol*. 2021;22(5):578–81.
- Anders CK, Carey LA. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. *Clin Breast Cancer*. 2009;9 Suppl 2(Suppl 2):S73–81.
- Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. *J Clin Oncol*. 2008;26(8):1275–81.
- Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. *N Engl J Med*. 2022;386(6):556–67.
- Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. *N Engl J Med*. 2017;376(22):2147–59.
- Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. *N Engl J Med*. 2021;384(25):2394–405.
- Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, et al. VP7–2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC. *Ann Oncol*. 2021;32(9):1198–200.
- Veninga V, Voest EE. Tumor organoids: opportunities and challenges to guide precision medicine. *Cancer Cell*. 2021;39(9):1190–201.
- Letai A, Bhola P, Welm AL. Functional precision oncology: testing tumors with drugs to identify vulnerabilities and novel combinations. *Cancer Cell*. 2022;40(1):26–35.
- Verduin M, Hoeben A, De Ruyscher D, Vooijs M. Patient-derived cancer organoids as predictors of treatment response. *Front Oncol*. 2021;11:641980.
- Sachs N, de Ligt J, Kopper O, Gogola E, Bounova G, Weeber F, et al. A living biobank of breast cancer organoids captures disease heterogeneity. *Cell*. 2018;172(1–2):373–386.e10.
- Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernández-Mateos J, Khan K, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. *Science*. 2018;359(6378):920–6.
- Beutel AK, Schütte L, Scheible J, Roger E, Müller M, Perkhof L, et al. A prospective feasibility trial to challenge patient-derived pancreatic cancer organoids in predicting treatment response. *Cancers (Basel)*. 2021;13(11):2539.
- Park M, Kwon J, Kong J, Moon SM, Cho S, Yang KY, et al. A patient-derived organoid-based radiosensitivity model for the prediction of radiation responses in patients with rectal cancer. *Cancers (Basel)*. 2021;13(15):3760.
- Walsh AJ, Cook RS, Sanders ME, Aurisicchio L, Ciliberto G, Arteaga CL, et al. Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer. *Cancer Res*. 2014;74(18):5184–94.
- Campaner E, Zannini A, Santorsola M, Bonazza D, Bottin C, Cancila V, et al. Breast cancer organoids model patient-specific response to drug treatment. *Cancers*. 2020;12(12):3869.
- Neal JT, Li X, Zhu J, Giangarra V, Grzeskowiak CL, Ju J, et al. Organoid modeling of the tumor immune microenvironment. *Cell*. 2018;175(7):1972–1988.e16.
- Martin SZ, Wagner DC, Hörner N, Horst D, Lang H, Tagscherer KE, et al. Ex vivo tissue slice culture system to measure drug-response rates of hepatic metastatic colorectal cancer. *BMC Cancer*. 2019;19(1):1030.
- Saleh R, Toor SM, Al-Ali D, Sasidharan Nair V, Elkord E. Blockade of PD-1, PD-L1, and TIM-3 altered distinct immune- and cancer-related signaling pathways in the transcriptome of human breast cancer explants. *Genes*. 2020;11(6):703.
- Fan TW, Higashi RM, Song H, Daneshmandi S, Mahan AL, Purdom MS, et al. Innate immune activation by checkpoint inhibition in human patient-derived lung cancer tissues. *eLife*. 2021;10:e69578.
- Nozaki K, Mochizuki W, Matsumoto Y, Matsumoto T, Fukuda M, Mizutani T, et al. Co-culture with intestinal epithelial organoids allows efficient expansion and motility analysis of intraepithelial lymphocytes. *J Gastroenterol*. 2016;51(3):206–13.
- Kong JCH, Guerra GR, Millen RM, Roth S, Xu H, Neeson PJ, et al. Tumor-infiltrating lymphocyte function predicts response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. *JCO Precis Oncol*. 2018;2:1–15.
- Bonnereau J, Courau T, Asesio N, Salfati D, Bouhidel F, Corte H, et al. Autologous T cell responses to primary human colorectal cancer spheroids are enhanced by ectonucleotidase inhibition. *Gut*. 2023;72(4):699–709.
- Hammoudi N, Hamoudi S, Bonnereau J, Bottonis H, Pérez K, Bezault M, et al. Autologous organoid co-culture model reveals T cell-driven epithelial cell death in Crohn's Disease. *Front Immunol*. 2022;13:1008456.
- Tsai S, McOlash L, Palen K, Johnson B, Duris C, Yang Q, et al. Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models. *BMC Cancer*. 2018;18(1):335.
- Holokai L, Chakrabarti J, Lundy J, Croagh D, Adhikary P, Richards SS, et al. Murine- and human-derived autologous organoid/immune cell co-cultures as pre-clinical models of pancreatic ductal adenocarcinoma. *Cancers (Basel)*. 2020;12(12):E3816.
- Dijkstra KK, Cattaneo CM, Weeber F, Chalabi M, van de Haar J, Fanchi LF, et al. Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids. *Cell*. 2018;174(6):1586–1598.e12.
- Perréard M, Florent R, Divoux J, Grellard JM, Lequesne J, Briand M, et al. ORGAVADS: establishment of tumor organoids from head and neck squamous cell carcinoma to assess their response to innovative therapies. *BMC Cancer*. 2023;23(1):1–9.
- Porter RJ, Murray GI, McLean MH. Current concepts in tumour-derived organoids. *Br J Cancer*. 2020;123(8):1209–18.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.